Pharmaceutical Regulatory Affairs Market
Pharmaceutical Regulatory Affairs Research Report 2025-2030: Entry of Companies into the Global Market Fueling Growth
23 janv. 2025 07h45 HE | Research and Markets
Dublin, Jan. 23, 2025 (GLOBE NEWSWIRE) -- The "Pharmaceutical Regulatory Affairs Market Size, Share & Trends Analysis Report By Service Provider, By Service, By Category, By Indication, By...
Alkeus Pharma Logo 2024.png
Alkeus Pharmaceuticals Receives FDA Rare Pediatric Disease and Fast Track Designations for Gildeuretinol as a Treatment for Stargardt Disease
18 nov. 2024 09h16 HE | Alkeus Pharmaceuticals
Alkeus Pharmaceuticals, Inc. receives FDA Rare Pediatric Disease and Fast Track designations for gildeuretinol as a treatment for Stargardt Disease
Osteal logo_TM.png
Osteal Therapeutics Announces Positive 12-Month Results from the APEX Clinical Trial Program at the 2024 American Association of Hip and Knee Surgeons (AAHKS) Annual Meeting
14 nov. 2024 16h45 HE | Osteal Therapeutics
DALLAS, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Osteal Therapeutics, Inc. (“Osteal”), a clinical-stage biopharmaceutical company developing a new category of combination drug/device therapies for...
Alkeus Pharma Logo 2024.png
Alkeus Pharmaceuticals Announces Presentation of a TEASE-3 Study Update Showing Progression Stalled in Early-Stage Stargardt Disease Patients Treated with Gildeuretinol
18 juil. 2024 10h20 HE | Alkeus Pharmaceuticals
Alkeus Pharmaceuticals announces presentation of a TEASE-3 study update showing progression stalled in early-stage Stargardt disease
Alkeus Pharma Logo 2024.png
Accomplished Biotech Leader Michel Dahan Joins Alkeus as President and CEO
02 juil. 2024 08h30 HE | Alkeus Pharmaceuticals
Alkeus Pharmaceuticals, Inc. announced today that Michel Dahan has joined the company as President and Chief Executive Officer.
Osteal.jpg
Osteal Therapeutics Closes $50M Series D Financing to Support Approval and Commercial Launch of Lead Candidate
05 juin 2024 09h00 HE | Osteal Therapeutics
Osteal Therapeutics secured $50M in Series D financing led by Zimmer Biomet. The funds will advance VT-X7, a treatment for periprosthetic joint infection.
Alkeus Pharma Logo 2024.png
Alkeus Pharmaceuticals Announces Positive Interim Results Demonstrating No Signs of Disease Progression in Early-Stage Stargardt Disease Patients Treated with Gildeuretinol
08 mai 2024 09h00 HE | Alkeus Pharmaceuticals
Alkeus Pharmaceuticals announces interim data demonstrating no signs of disease progression in early-stage Stargardt patients treated with gildeuretinol.
22157.jpg
Paroxysmal Nocturnal Hemoglobinuria Treatment Advances with Comprehensive Danicopan Market Forecast to 2032
24 janv. 2024 10h44 HE | Research and Markets
Dublin, Jan. 24, 2024 (GLOBE NEWSWIRE) -- The "Danicopan Emerging Drug Insight and Market Forecast - 2032" report has been added to ResearchAndMarkets.com's offering. The global healthcare...
BioNTech und Duality
BioNTech und DualityBio erhalten Breakthrough-Therapy-Status der FDA für ADC-Kandidaten BNT323/DB-1303 zur Behandlung von Gebärmutterkrebs
21 déc. 2023 08h00 HE | BioNTech SE
Breakthrough-Therapy-Status basiert auf Phase-1/2-Daten zur Sicherheit und Wirksamkeit in Patientinnen mit Human Epidermal Growth Factor Receptor 2 („HER2“) -exprimierendem, fortgeschrittenen...
BioNTech and Duality
BioNTech and DualityBio Receive FDA Breakthrough Therapy Designation for Antibody-Drug Conjugate Candidate BNT323/DB-1303 in Endometrial Cancer
21 déc. 2023 08h00 HE | BioNTech SE
Designation is based on Phase 1/2 safety and efficacy data in patients with Human Epidermal Growth Factor Receptor 2 (“HER2”)-expressing advanced endometrial cancer with encouraging early signs of...